By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
AstraZeneca AB et al. v. Dr. Reddy's Laboratories, Ltd. et al.
3:08-cv-00328; filed January 17, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,714,504 ("Compositions," issued February 3, 1988), 6,875,872 ("Compounds," issued April 5, 2005), and 6,369,085 ("Form of S-omeprazole," issued April 9, 2002) following a paragraph IV certification as part of DRL's filing of an ANDA to manufacture a generic version of AstraZeneca's Nexium® (esomeprazole magnesium, used for the treatment of gastroesophageal reflux disease). View the complaint here.
IMPAX Laboratories, Inc. v. Medics Pharmaceutical Corp.
3:08-cv-00253; filed January 15, 2008 in the Northern District of California
Declaratory judgment of invalidity and non-infringement of U.S. Patent No. 5,908,838 ("Method for the Treatment of Acne," issued June 1, 1999) in conjunction with IMPAX's filing of an ANDA to manufacture a generic version of Medics' Solodyn® (minocycline hydrochloride extended release tablets, used to treat acne). View the complaint here.
Sanofi-Aventis U.S. LLC et al. v. Mustafa Nevzat Ilac Sanayii A.S. et al.
3:08-cv-00263; filed January 14, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,338,874 ("Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994) and 5,716,988 ("Pharmaceutically Stable Preparation of Oxaliplatinum," issued February 10, 1998) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the complaint here.
Aventis Pharmaceuticals Inc. v. Sandoz Inc.
2:08-cv-00254; filed January 11, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,135,571 ("Processes for Preparing Anhydrous and Hydrate Forms of Antihistaminic Piperidine Derivatives, Polymorphs and Pseudomorphs Thereof," issued November 14, 2006), following a paragraph IV certification as part of Sandoz's filing of two ANDAs to manufacture a generic version of Aventis' Allegra (fexofenadine hydrochloride) and Allegra-D® 12 Hour (fexofenadine hydrochloride/ pseudoephedrine) (both used to treat allergies). View the complaint here.
Forest Laboratories Inc. et al. v. Barr Laboratories Inc. et al.
1:08-cv-00022; filed January 10, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 5,061,703 ("Adamantane Derivatives in the Prevention and Treatment of Cerebral Ischemia," issued on October 29, 1991), following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Forest's Namenda® (memantine hydrochloride, used for the treatment of moderate to severe dementia of the Alzheimer's type). View the complaint here.
Forest Laboratories Inc. et al. v. Cobalt Laboratories Inc. et al.
1:08-cv-00021; filed January 10, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 5,061,703 ("Adamantane Derivatives in the Prevention and Treatment of Cerebral Ischemia," issued on October 29, 1991), following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Forest's Namenda® (memantine hydrochloride, used for the treatment of moderate to severe dementia of the Alzheimer's type). View the complaint here.
Earlier US5614560 was listed in orange book and subsequently delested for use of Namenda. Any consequences in litigation?
Posted by: Sam | January 20, 2008 at 10:14 PM